Stroke · Post‐menopausal women with pre‐exisiting cardiovascular disease
Hormone therapy showed no clear difference in stroke compared with placebo (moderate certainty).
1 finding from 1 review
Venous thromboembolism · Post‐menopausal women with pre‐exisiting cardiovascular disease
Hormone therapy leads to higher venous thromboembolism compared with placebo (high certainty).
1 finding from 1 review
All‐cause mortality · DCM (non‐ischaemic)
It is very uncertain whether stem cell therapy changes all‐cause mortality compared with control (very low certainty).
1 finding from 1 review
Procedural complications · DCM (non‐ischaemic)
1 finding from 1 review
Health‐related quality of life · DCM (non‐ischaemic)
1 finding from 1 review
Functional capacityAssessed: 6MWT · DCM (non‐ischaemic)
1 finding from 1 review
Performance status – change in functional class (NYHA) · DCM (non‐ischaemic)
1 finding from 1 review
MACE · DCM (non‐ischaemic)
1 finding from 1 review
Ventricular arrhythmias (within 30 days) · DCM (non‐ischaemic)
1 finding from 1 review
Outcomes length of · DCM (non‐ischaemic)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality (HR) ‐ main analysisa 16.5 to 67.6 months · DCM (non‐ischaemic)
ICD plus optimal medical therapy leads to lower all‐cause mortality (HR) ‐ main analysisa 16.5 to 67.6 months compared with optimal medical therapy alone (high certainty).
1 finding from 1 review
Cardiovascular mortality · DCM (non‐ischaemic)
ICD plus optimal medical therapy showed no clear difference in cardiovascular mortality (RR)b 22.8 to 67.6 months compared with optimal medical therapy alone (moderate certainty).
1 finding from 1 review
Sudden cardiac death · DCM (non‐ischaemic)
ICD plus optimal medical therapy leads to lower sudden cardiac death (HR)a 24 to 67.6 months compared with optimal medical therapy alone (high certainty).
1 finding from 1 review
Adverse events 67.7 months · DCM (non‐ischaemic)
1 finding from 1 review
Noncardiovascular mortality (RR)b 22.8 to 67.6 months · DCM (non‐ischaemic)
ICD plus optimal medical therapy showed no clear difference in noncardiovascular mortality (RR)b 22.8 to 67.6 months compared with optimal medical therapy alone (moderate certainty).
1 finding from 1 review
Health‐related quality of life 24 to 29 months · DCM (non‐ischaemic)
1 finding from 1 review
First ICD‐related hospitalisation ‐ not reported · DCM (non‐ischaemic)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of patients died of cardiac failure ‐ Astragaloside injection versus support therapy · patients with viral myocarditis
It is very uncertain whether herbal medicines changes number of patients died of cardiac failure: Astragaloside injection… compared with supportive therapy (very low certainty).
1 finding from 1 review
Number of patients with premature beat ‐ Xinshu Capsule versus supportive therapy · patients with viral myocarditis
It is very uncertain whether herbal medicines changes number of patients with premature beat: Xinshu capsule versus… compared with supportive therapy (very low certainty).
1 finding from 1 review
All‐cause mortality · patients with stable angina pectoris
Ranolazine (monotherapy) showed no clear difference in all‐cause mortality compared with placebo (low certainty).
1 finding from 1 review